NCT04385173 is a Phase 1 clinical trial of B7-H3 CAR-T in Recurrent Glioblastoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04385173?

NCT04385173 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04385173?

Interventions in NCT04385173: B7-H3 CAR-T, Temozolomide.

What condition does NCT04385173 study?

NCT04385173 studies Recurrent Glioblastoma, Refractory Glioblastoma.

Is NCT04385173 still recruiting?

NCT04385173 is currently status unknown. Last updated 28 December 2022.

Last reviewed 2022-12-28 · How we verify

NCT04385173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

Status unknown Phase 1 Last updated 28 December 2022

What this trial tests

Phase 1 trial testing B7-H3 CAR-T in Recurrent Glioblastoma in 12 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
1 March 2024

1 May 2024

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 December 2022
Primary completion	1 March 2024
Estimated completion	1 May 2024
Sites	1 location across China

Drugs / interventions tested

B7-H3 CAR-T — full drug profile →
Temozolomide (temozolomide) — full drug profile →

Conditions studied

Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
Refractory Glioblastoma — all drugs for Refractory Glioblastoma →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Recurrent Glioblastoma or Refractory Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, Lafortune F, et al · · 2021 · cited 532× · PMID 34302977 · DOI 10.1016/j.phrs.2021.105780
B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F, Michelakos T, Kurokawa T, Sadagopan A, et al · · 2021 · cited 311× · PMID 33051306 · DOI 10.1158/1078-0432.ccr-20-2584
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J, Wickman E, DeRenzo C, Gottschalk S. · · 2020 · cited 284× · PMID 32979309 · DOI 10.1016/j.ymthe.2020.09.015
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT, Jin WL. · · 2021 · cited 204× · PMID 34349762 · DOI 10.3389/fimmu.2021.701006
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B, Li H, Xia Y, Wang Y, et al · · 2022 · cited 145× · PMID 36284349 · DOI 10.1186/s13045-022-01364-7
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
Maggs L, Cattaneo G, Dal AE, Moghaddam AS, et al · · 2021 · cited 113× · PMID 34113233 · DOI 10.3389/fnins.2021.662064

Verify or expand the search:

Other trials of B7-H3 CAR-T

Trials testing the same drug.

NCT04077866 — B7-H3 CAR-T for Recurrent or Refractory Glioblastoma · Phase 1, PHASE2 · unknown

Other recruiting trials for Recurrent Glioblastoma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04385173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 28 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04385173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing